Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy

被引:37
作者
Bellone, Graziella [1 ]
Novarino, Anna [2 ]
Vizio, Barbara [1 ]
Brondino, Gabriele [1 ]
Addeo, Alfredo [4 ]
Prati, Adriana [1 ]
Giacobino, Alice [2 ]
Campra, Donata [3 ]
Fronda, Gian Ruggero [3 ]
Ciuffreda, Libero [2 ]
机构
[1] Univ Turin, Dept Clin Physiopathol, I-10126 Turin, Italy
[2] San Giovanni Battista Molinette Hosp, Dept Clin Oncol, Turin, Italy
[3] San Giovanni Battista Molinette Hosp, Dept Surg, Turin, Italy
[4] San Giovanni Bosco Hosp, ASLTO2, Turin, Italy
关键词
pancreatic carcinoma; tumor immunity; chemotherapy; immunotherapy; surgery; PERIPHERAL-BLOOD LYMPHOCYTES; CIRCULATING DENDRITIC CELLS; MEDIATED ANTITUMOR IMMUNITY; ANTIGEN CROSS-PRESENTATION; ACTIVATED KILLER-CELLS; REGULATORY T-CELLS; BREAST-CANCER; NATURAL-KILLER; CLASS-I; INNATE RESISTANCE;
D O I
10.3892/ijo_00000301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As surgery and chemotherapy may act as adjuvants providing antitumor immunity benefits, we ran phenotypical and functional immunomonitoring in patients with resectable pancreatic adenocarcinoma and advanced metastatic disease receiving combined treatment (cisplatin, gemcitabine, 5-FU). Blood was taken before/one month after resection; before/during chemotherapy. Controls were age- and gender-matched. Circulating lymphocyte, myeloid and plasmacytoid dendritic cell (MDC and PDC) subsets were examined by flow cytometry; functional activity by mixed lymphocyte reaction (MLR) for DC allostimulation, through 4-h Cr-51-release assay for Natural Killer (NK) and lymphokine-activated-killer (LAK) cell cytotoxicity; ELISA for spontaneous/activated cytokine release by PBMC and T cells. Significant differences Occurred in several parameters between pretreatment patient and control values: fewer CD8(+) cells and increased apoptosis-prone CD3(+)/CD95(+) lymphocytes, higher frequency of MDC, reduced allostimulatory activity by ex vivo-generated DC, depressed LAK activity, elevated IL-10 and IL-12p40 production; impaired IL-12p70 and IFN-gamma production by stimulated PBMC and T cells. Only IL-12p70 level was correlated with survival. One month after radical, but not palliative surgery, the percentage of T-lymphocytes coexpressing CD3/CD95 decreased significantly, the stimulatory capacity of DC increased, and LPS-induced IL-12p70 release by PBMC rose concomitantly with the anti-CD3 stimulated-IFN-gamma production by T cells. In patients with locally advanced or metastatic disease, one and/or two combined drug cycles increased percentage of CD4 cells and LAK cell cytotoxicity and decreased PDC frequency and spontaneous/LPS-stimulated IL-10 by PBMC. Results suggest immunological changes induced by surgical resection/combined chemotherapy indicate specific precisely-timed windows of opportunity for introducing immunotherapy in pancreatic cancer, possibly improving survival in this highly lethal disease.
引用
收藏
页码:1701 / 1715
页数:15
相关论文
共 86 条
  • [1] Past and present treatment of pancreatic adenocarcinoma: Chemotherapy as a standard treatment modality
    Abbruzzese, JL
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (06) : 2 - 8
  • [2] Almand B, 2000, CLIN CANCER RES, V6, P1755
  • [3] CANCER, CYTOKINES, AND CYTOTOXIC-CELLS - INTERLEUKIN-2 IN THE IMMUNOTHERAPY OF HUMAN NEOPLASMS
    ATZPODIEN, J
    KIRCHNER, H
    [J]. KLINISCHE WOCHENSCHRIFT, 1990, 68 (01): : 1 - 11
  • [4] Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes
    Audia, S.
    Nicolas, A.
    Cathelin, D.
    Larmonier, N.
    Ferrand, C.
    Foucher, P.
    Fanton, A.
    Bergoin, E.
    Maynadie, M.
    Arnould, L.
    Bateman, A.
    Lorcerie, B.
    Solary, E.
    Chauffert, B.
    Bonnotte, B.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (03) : 523 - 530
  • [5] BALCH CM, 1985, SURGERY, V98, P151
  • [6] Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer
    Bauernhofer, T
    Kuss, I
    Henderson, B
    Baum, AS
    Whiteside, TL
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (01) : 119 - 124
  • [7] BAXEVANIS CN, 1993, CANCER-AM CANCER SOC, V72, P491, DOI 10.1002/1097-0142(19930715)72:2<491::AID-CNCR2820720227>3.0.CO
  • [8] 2-1
  • [9] Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients
    Bellone, G
    Turletti, A
    Artusio, E
    Mareschi, K
    Carbone, A
    Tibaudi, D
    Robecchi, A
    Emanuelli, G
    Rodeck, U
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) : 537 - 547
  • [10] Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival
    Bellone, G
    Smirne, C
    Mauri, FA
    Tonel, E
    Carbone, A
    Buffolino, A
    Dughera, L
    Robecchi, A
    Pirisi, M
    Emanuelli, G
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) : 684 - 698